bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Data from A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
Authors: Beltran Himisha , Oromendia Clara , Danila Daniel C. , Montgomery Bruce , Hoimes Christopher , Szmulewitz Russell Z. , Vaishampayan Ulka , Armstrong Andrew J. , Stein Mark , Pinski Jacek , Mosquera Juan M. , Sailer Verena , Bareja Rohan , Romanel Alessandro , Gumpeni Naveen , Sboner Andrea , Dardenne Etienne , Puca Loredana , Prandi Davide , Rubin Mark A. , Scher Howard I. , Rickman David S. , Demichelis Francesca , Nanus David M. , Ballman Karla V. , Tagawa Scott T.
Published: April 2023

Supplementary Data
Supplementary Figures from Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer
Authors: Mostaghel Elahe A. , Zhang Ailin , Hernandez Susana , Marck Brett T. , Zhang Xiaotun , Tamae Daniel , Biehl Heather E. , Tretiakova Maria , Bartlett Jon , Burns John , Dumpit Ruth , Ang Lisa , Matsumoto Alvin M. , Penning Trevor M. , Balk Steven P. , Morrissey Colm , Corey Eva , True Lawrence D. , Nelson Peter S.
Published: April 2023

Supplementary Figs S1-S6
Supplementary Figure Legends from Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials
Authors: Terbuch Angelika , Tiu Crescens , Candilejo Irene Moreno , Scaranti Mariana , Curcean Andra , Bar Dan , Estevez Timon Miriam , Ameratunga Malaka , Ang Joo Ern , Ratoff Jonathan , Minchom Anna R. , Banerji Udai , de Bono Johann S. , Tunariu Nina , Lopez Juanita S.
Published: April 2023

Figure S1A. Correlation of patterns of DILD as per ATS/ERS classification and clinical severity. AIP correlated significantly with worse severity (P=0.002). NSIP, non-specific interstitial pneumonia; COP, cryptogenic organizing pneumonia; AIP, acute interstitial pneumonia; HP, hypersensitivity pneumonitis. Figure S1B. A higher RMH DILD score predicts for increasing clinical severity of DILD as per CTCAE grading. Shown are CTCAE grading and RMH DILD Score at the time of DILD detection. Box plot mapping RMH DILD Scores against CTCAE grading showing statistically significant worsening of CTCAE grading and symptoms with higher RMH DILD score (P=0.004); DILD was confirmed to be the cause of death in one patient who had an initial RMH DILD score of 5 and was asymptomatic with an excellent partial response to therapy and so was continued on therapy. This patient then developed symptomatic DILD with a worsening RMH DILD score of 8, deteriorated and died. RMH DILD score, Royal Marsden Hospital Score for drug induced interstitial lung disease; CTCAE, Common Terminology Criteria for Adverse Events Version 5.0. Figure S2. Continuation of IMP following radiological detection of asymptomatic DILD resulting in clinical deterioration. Images from a patient with breast cancer treated with an investigational drug-conjugate. Patient had no prior lung disease and no lung metastases at baseline. Cartoons (left) show RMH DILD scoring of matched sagittal radiographic images (right). The first row shows initial development of radiographic changes after 2 cycles of treatment when patient was asymptomatic (RMH DILD score of 5) and otherwise had a remarkable RECIST PR. With a further cycle of treatment, the changes had significantly worsened (RMH DILD score of 8), with development of rapidly progressive clinical symptoms which was ultimately fatal despite treatment with antibiotics, steroids, and respiratory support.
Figure S2 from Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials
Authors: Terbuch Angelika , Tiu Crescens , Candilejo Irene Moreno , Scaranti Mariana , Curcean Andra , Bar Dan , Estevez Timon Miriam , Ameratunga Malaka , Ang Joo Ern , Ratoff Jonathan , Minchom Anna R. , Banerji Udai , de Bono Johann S. , Tunariu Nina , Lopez Juanita S.
Published: April 2023

Figure S2. Continuation of IMP following radiological detection of asymptomatic DILD resulting in clinical deterioration.
Figure S1 from Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials
Authors: Terbuch Angelika , Tiu Crescens , Candilejo Irene Moreno , Scaranti Mariana , Curcean Andra , Bar Dan , Estevez Timon Miriam , Ameratunga Malaka , Ang Joo Ern , Ratoff Jonathan , Minchom Anna R. , Banerji Udai , de Bono Johann S. , Tunariu Nina , Lopez Juanita S.
Published: April 2023

Figure S1A. Correlation of patterns of DILD as per ATS/ERS classification and clinical severity. Figure S1B. A higher RMH DILD score predicts for increasing clinical severity of DILD as per CTCAE grading.
Supplementary Figure 1 from Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer
Authors: Karam Sana D. , Reddy Krishna , Blatchford Patrick J. , Waxweiler Tim , DeLouize Alicia M. , Oweida Ayman , Somerset Hilary , Marshall Carrie , Young Christian , Davies Kurtis D. , Kane Madeleine , Tan Aik Choo , Wang Xiao Jing , Jimeno Antonio , Aisner Dara L. , Bowles Daniel W. , Raben David
Published: April 2023

Schema Utilizing Time-to-Event Continual Reassessment Method (TITE-CRM) Design
Supplementary Table S9 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Table S9
Supplementary Table S8 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Table S8
Supplementary Figure 5 from Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy
Authors: Marciscano Ariel E. , Ghasemzadeh Ali , Nirschl Thomas R. , Theodros Debebe , Kochel Christina M. , Francica Brian J. , Muroyama Yuki , Anders Robert A. , Sharabi Andrew B. , Velarde Esteban , Mao Wendy , Chaudhary Kunal R. , Chaimowitz Matthew G. , Wong John , Selby Mark J. , Thudium Kent B. , Korman Alan J. , Ulmert David , Thorek Daniel L.J. , DeWeese Theodore L. , Drake Charles G.
Published: April 2023

Comparison of intratumoral Treg depletion by anti-CTLA4 Ig2Ga and IgG2b isotypes.
Supplementary Table S4 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Table S4
Supplementary Table S2 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Table S2
Supplementary Table S1 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Table S1
Supplementary Figure legend from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Figure legend
Supplementary Figure 1 from A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non–Small Cell Lung Cancer
Authors: Cascone Tina , Sepesi Boris , Lin Heather Y. , Kalhor Neda , Parra Edwin R. , Jiang Mei , Godoy Myrna C.B. , Zhang Jianjun , Fossella Frank V. , Tsao Anne S. , Lam Vincent K. , Lu Charles , Mott Frank E. , Simon George R. , Antonoff Mara B. , Mehran Reza J. , Rice David C. , Behrens Carmen , Weissferdt Annikka , Moran Cesar , Vaporciyan Ara A. , Lee J. Jack , Swisher Stephen G. , Gibbons Don L. , Wistuba Ignacio I. , William William N. , Heymach John V.
Published: April 2023

Supplementary Figure 1
Supplementary figure 1 legend from Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma
Authors: Figlin Robert A. , Tannir Nizar M. , Uzzo Robert G. , Tykodi Scott S. , Chen David Y.T. , Master Viraj , Kapoor Anil , Vaena Daniel , Lowrance William , Bratslavsky Gennady , DeBenedette Mark , Gamble Alicia , Plachco Ana , Norris Marcus S. , Horvatinovich Joe , Tcherepanova Irina Y. , Nicolette Charles A. , Wood Christopher G.
Published: April 2023

supplementary figure 1 legend
Supplementary Figure 1 from Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial
Authors: Weathers Shiao-Pei , Penas-Prado Marta , Pei Be-Lian , Ling Xiaoyang , Kassab Cynthia , Banerjee Pinaki , Bdiwi Mustafa , Shaim Hila , Alsuliman Abdullah , Shanley Mayra , de Groot John F. , O'Brien Barbara J. , Harrison Rebecca , Majd Nazanin , Kamiya-Matsuoka Carlos , Fuller Gregory N. , Huse Jason T. , Chi Linda , Rao Ganesh , Weinberg Jeffrey S. , Lang Frederick F. , Sawaya Raymond , Shpall Elizabeth J. , Rezvani Katayoun , Heimberger Amy B.
Published: April 2023

Supplementary Figure 1
Table S4 from Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer
Authors: Whittle James R. , Vaillant François , Surgenor Elliot , Policheni Antonia N. , Giner Göknur , Capaldo Bianca D. , Chen Huei-Rong , Liu He K. , Dekkers Johanna F. , Sachs Norman , Clevers Hans , Fellowes Andrew , Green Thomas , Xu Huiling , Fox Stephen B. , Herold Marco J. , Smyth Gordon K. , Gray Daniel H.D. , Visvader Jane E. , Lindeman Geoffrey J.
Published: April 2023

Targeted gene sequencing of patient derived organoids
Supplementary materials from ATP-Citrate Lyase Epigenetically Potentiates Oxidative Phosphorylation to Promote Melanoma Growth and Adaptive Resistance to MAPK Inhibition
Authors: Guo Weinan , Ma Jinyuan , Yang Yuqi , Guo Sen , Zhang Weigang , Zhao Tao , Yi Xiuli , Wang Huina , Wang Shiyu , Liu Yu , Dai Wei , Chen Xuguang , Shi Qiong , Wang Gang , Gao Tianwen , Li Chunying
Published: April 2023

Supplementary figures, tables and figure legends
Figure S2 from Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer
Authors: Townsend Amanda , Tebbutt Niall , Karapetis Christos , Cooper Pamela , Singhal Nimit , Yeend Susan , Pirc Louise , Joshi Rohit , Hardingham Jennifer , Price Timothy
Published: April 2023

Kaplan-Meier Survival Curves for Biomarker Substudy (n=33)
Supplementary data file from ATP-Citrate Lyase Epigenetically Potentiates Oxidative Phosphorylation to Promote Melanoma Growth and Adaptive Resistance to MAPK Inhibition
Authors: Guo Weinan , Ma Jinyuan , Yang Yuqi , Guo Sen , Zhang Weigang , Zhao Tao , Yi Xiuli , Wang Huina , Wang Shiyu , Liu Yu , Dai Wei , Chen Xuguang , Shi Qiong , Wang Gang , Gao Tianwen , Li Chunying
Published: April 2023

mRNA expression profile analysis
Figure S1 from Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer
Authors: Townsend Amanda , Tebbutt Niall , Karapetis Christos , Cooper Pamela , Singhal Nimit , Yeend Susan , Pirc Louise , Joshi Rohit , Hardingham Jennifer , Price Timothy
Published: April 2023

Consort Diagram
Table S3 from Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression
Authors: Marcon Julian , DiNatale Renzo G. , Sanchez Alejandro , Kotecha Ritesh R. , Gupta Sounak , Kuo Fengshen , Makarov Vladimir , Sandhu Amar , Mano Roy , Silagy Andrew W. , Blum Kyle A. , Nassau Daniel E. , Benfante Nicole E. , Ortiz Michael V. , Carlo Maria I. , Chan Timothy A. , Motzer Robert J. , Voss Martin H. , Coleman Jonathan , Russo Paul , Reuter Victor , Hakimi A. Ari , Reznik Ed
Published: April 2023

Table S3 contains the mutation annotation files of the MSK-IMPACT cohort and the exam cohorts
Supplementary Figure S6 from Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFβ-Induced Breast Cancer Metastasis
Authors: Liu Sijia , González-Prieto Román , Zhang Mengdi , Geurink Paul P. , Kooij Raymond , Iyengar Prasanna Vasudevan , van Dinther Maarten , Bos Erik , Zhang Xiaobing , Le Dévédec Sylvia E. , van de Water Bob , Koning Roman I. , Zhu Hong-Jian , Mesker Wilma E. , Vertegaal Alfred C.O. , Ovaa Huib , Zhang Long , Martens John W.M. , ten Dijke Peter
Published: April 2023

Supplementary Figure S6. Related to Figure 5 and 6. A, Mass spectrometry analysis reveals covalent binding of 6RK73 to UCHL1. B, Western blot of SMAD3 and pSMAD3 in MDA-MB-436 cells treated with or without 6RK73 and shUCHL1 cells. Same blot was used for UCHL1 and GAPDH (loading control). pSMAD3 and SMAD3 results were obtained from another two blots using the same corresponding cell lysates. C, ELISA analysis of UCHL1 levels in serum samples from ER positive and ER negative breast cancer patients. P=0.1627, unpaired Student t test. D, Immunofluorescence staining of pSMAD2 in MDA-MB-436 UCHL1 stable known down cells treated with exosomes isolated from PLKO or shUCHL1 MDA-MB-436 cells that were labelled with green PKH67 exosomes dye.
Figure S2 from Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression
Authors: Marcon Julian , DiNatale Renzo G. , Sanchez Alejandro , Kotecha Ritesh R. , Gupta Sounak , Kuo Fengshen , Makarov Vladimir , Sandhu Amar , Mano Roy , Silagy Andrew W. , Blum Kyle A. , Nassau Daniel E. , Benfante Nicole E. , Ortiz Michael V. , Carlo Maria I. , Chan Timothy A. , Motzer Robert J. , Voss Martin H. , Coleman Jonathan , Russo Paul , Reuter Victor , Hakimi A. Ari , Reznik Ed
Published: April 2023

Figure S2 shows boxplots displaying median values for PD-L1 and angiogenesis gene signatures in KIRP and KIRC cohorts (tRCC vs. non-tRCC)
Supplementary Figure S3 from Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFβ-Induced Breast Cancer Metastasis
Authors: Liu Sijia , González-Prieto Román , Zhang Mengdi , Geurink Paul P. , Kooij Raymond , Iyengar Prasanna Vasudevan , van Dinther Maarten , Bos Erik , Zhang Xiaobing , Le Dévédec Sylvia E. , van de Water Bob , Koning Roman I. , Zhu Hong-Jian , Mesker Wilma E. , Vertegaal Alfred C.O. , Ovaa Huib , Zhang Long , Martens John W.M. , ten Dijke Peter
Published: April 2023

Supplementary Figure S3. Related to Figure 4. A, qPCR analysis of mesenchymal markers in UCHL1 shRNA knock down MDA-MB-436 cells versus NT and PLKO control infected cells. *, P < 0.05, two-way ANOVA. B, Western blot analysis of AKT and HIF1Î± expression levels in UCHL1 shRNA knock down MDA-MB-436 cells versus NT and PLKO control infected cells. Same blot was used for HIF1Î± and Tubulin (loading control). UCHL1 and AKT were from another blot using the same corresponding cell lysates. C, TGFÎ²-induced SMAD3/SMAD4-dependent CAGA12-Luc transcriptional reporter analysis upon UCHL1 overexpression (left) and UCHL1 shRNA knock down (right) in HEK293T cell lines. *, P < 0.05, ***, P < 0.001 and ****, P < 0.0001, two-way ANOVA. D, Interaction of UCHL1 and TÎ²RI as detected by immunoprecipitation (IP) of Flag-tagged UCHL1 and immunoblot (IB) for endogenous TÎ²RI in HEK293T cells. IP results using Tï�¢RI and UCHL1 antibodies were obtained from the same blot. Input blotting results using Tï�¢RI and UCHL1 antibodies were obtained from another blot using the same cell lysates as for IP. E, In vitro interaction of recombinant UCHL1 protein with TÎ²RI that is ubiquitinated (isolated by IP from Tï�¢R1 transfected cells treated with TGF-ï�¢) and TÎ²RI with low levels of ubiquitination (Tï�¢RI was treated with a general DUB USP16 to remove attached ubiquitin from TÎ²RI). All results were obtained from one blot. F, Quantification of PLA analysis of endogenous interaction between UCHL1 and SMAD2 in A549 cells. Number of dots per cell in control and TGFÎ² (5 ng/ml) groups in SMAD2-UCHL1 PLA are shown. ns, not significant, unpaired Student t test. G, Western blot of UCHL1 in A549 PLKO and shUCHL1 cells. Same blot was used for UCHL1 and GAPDH (loading control). H, PLA of TÎ²RI-UCHL1 and SMAD2-UCHL1 in PLKO and shUCHL1 A549 cells treated with or without 5 ng/ml TGFÎ² for 1 hr.
Supplementary information from Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer
Authors: Garrido Marine F. , Martin Nicolas J.-P. , Bertrand Matthieu , Gaudin Catherine , Commo Frédéric , El Kalaany Nassif , Al Nakouzi Nader , Fazli Ladan , Del Nery Elaine , Camonis Jacques , Perez Franck , Lerondel Stéphanie , Le Pape Alain , Compagno Daniel , Gleave Martin , Loriot Yohann , Désaubry Laurent , Vagner Stéphan , Fizazi Karim , Chauchereau Anne
Published: April 2023

Supplementary material and methods
Figure S6 from Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy
Authors: Ladjohounlou Riad , Lozza Catherine , Pichard Alexandre , Constanzo Julie , Karam Jihad , Le Fur Pierre , Deshayes Emmanuel , Boudousq Vincent , Paillas Salomé , Busson Muriel , Le Blay Marion , Jarlier Marta , Marcatili Sara , Bardiès Manuel , Bruchertseifer Frank , Morgenstern Alfred , Torgue Julien , Navarro-Teulon Isabelle , Pouget Jean-Pierre
Published: April 2023

SUPPLEMENTARY FIG. S6. Signaling pathways activated in SK-OV-3MISRII donor cells exposed to 213Bi-anti-MISRII mAb + filipin and in recipient cells.
Figure S1 from Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer
Authors: Garrido Marine F. , Martin Nicolas J.-P. , Bertrand Matthieu , Gaudin Catherine , Commo Frédéric , El Kalaany Nassif , Al Nakouzi Nader , Fazli Ladan , Del Nery Elaine , Camonis Jacques , Perez Franck , Lerondel Stéphanie , Le Pape Alain , Compagno Daniel , Gleave Martin , Loriot Yohann , Désaubry Laurent , Vagner Stéphan , Fizazi Karim , Chauchereau Anne
Published: April 2023

Chemoresistant cell lines
Supplementary material 3. from Enhancing Abiraterone Acetate Efficacy in Androgen Receptor–positive Triple-negative Breast Cancer: Chk1 as a Potential Target
Authors: Grellety Thomas , Callens Celine , Richard Elodie , Briaux Adrien , Vélasco Valérie , Pulido Marina , Gonçalves Anthony , Gestraud Pierre , MacGrogan Gaetan , Bonnefoi Hervé , Cardinaud Bruno
Published: April 2023

List of the 760 transcripts used in the custom Nanostring panel for RNA analyses
Figure S2 from Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy
Authors: Ladjohounlou Riad , Lozza Catherine , Pichard Alexandre , Constanzo Julie , Karam Jihad , Le Fur Pierre , Deshayes Emmanuel , Boudousq Vincent , Paillas Salomé , Busson Muriel , Le Blay Marion , Jarlier Marta , Marcatili Sara , Bardiès Manuel , Bruchertseifer Frank , Morgenstern Alfred , Torgue Julien , Navarro-Teulon Isabelle , Pouget Jean-Pierre
Published: April 2023

SUPPLEMENTARY FIG. S2. Clonogenic cell survival of donor and recipient cells after exposure to unlabeled mAbs.
Figure S1 from Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy
Authors: Ladjohounlou Riad , Lozza Catherine , Pichard Alexandre , Constanzo Julie , Karam Jihad , Le Fur Pierre , Deshayes Emmanuel , Boudousq Vincent , Paillas Salomé , Busson Muriel , Le Blay Marion , Jarlier Marta , Marcatili Sara , Bardiès Manuel , Bruchertseifer Frank , Morgenstern Alfred , Torgue Julien , Navarro-Teulon Isabelle , Pouget Jean-Pierre
Published: April 2023

SUPPLEMENTARY FIG. S1. (A) 212Pb (red) decays into 212Bi by emitting a beta minus particle.
Supplementary figure S2. from Enhancing Abiraterone Acetate Efficacy in Androgen Receptor–positive Triple-negative Breast Cancer: Chk1 as a Potential Target
Authors: Grellety Thomas , Callens Celine , Richard Elodie , Briaux Adrien , Vélasco Valérie , Pulido Marina , Gonçalves Anthony , Gestraud Pierre , MacGrogan Gaetan , Bonnefoi Hervé , Cardinaud Bruno
Published: April 2023

Distribution of patients by response status based on a restricted list of 41 transcripts present in our custom NanoString panel and in the list of transcripts of the first two studies which identified the MA sub-type (1) and the class A sub-type (2). Non-supervised Heatmap of genes discriminating molecular apocrine versus basal tumors in the Farmer et al. and Doane et al. papers, n=41 genes, and present in the Nanostring PanCancer pathway panel.
Supplemental Tables from Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer
Authors: Feng Bohai , Shen Ying , Pastor Hostench Xavier , Bieg Matthias , Plath Michaela , Ishaque Naveed , Eils Roland , Freier Kolja , Weichert Wilko , Zaoui Karim , Hess Jochen
Published: April 2023

Supplemental Tables_revised
Supplemental Figure Legends from Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
Authors: Kugel Curtis H. , Douglass Stephen M. , Webster Marie R. , Kaur Amanpreet , Liu Qin , Yin Xiangfan , Weiss Sarah A. , Darvishian Farbod , Al-Rohil Rami N. , Ndoye Abibatou , Behera Reeti , Alicea Gretchen M. , Ecker Brett L. , Fane Mitchell , Allegrezza Michael J. , Svoronos Nikolaos , Kumar Vinit , Wang Daniel Y. , Somasundaram Rajasekharan , Hu-Lieskovan Siwen , Ozgun Alpaslan , Herlyn Meenhard , Conejo-Garcia Jose R. , Gabrilovich Dmitry , Stone Erica L. , Nowicki Theodore S. , Sosman Jeffrey , Rai Rajat , Carlino Matteo S. , Long Georgina V. , Marais Richard , Ribas Antoni , Eroglu Zeynep , Davies Michael A. , Schilling Bastian , Schadendorf Dirk , Xu Wei , Amaravadi Ravi K. , Menzies Alexander M. , McQuade Jennifer L. , Johnson Douglas B. , Osman Iman , Weeraratna Ashani T.
Published: April 2023

Figure Legends for Supplemental Data
Supplementary Tables S1-S6 from Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease–Associated Colorectal Cancers
Authors: Din Shahida , Wong Kim , Mueller Mike F. , Oniscu Anca , Hewinson James , Black Catherine J. , Miller Martin L. , Jiménez-Sánchez Alejandro , Rabbie Roy , Rashid Mamunar , Satsangi Jack , Adams David J. , Arends Mark J.
Published: April 2023

Supplementary Table S1 Phenotypic characteristics of IBD-CRC cases. Supplementary Table S2A Selected somatic mutations in IBD-CRC hypermutators. Supplementary Table S2B Selected somatic mutations in IBD-CRC non-hypermutators. Supplementary Table S3 Cosine similarities of IBD-CRC signatures and Alexandrov signatures. Supplementary Table S4 Genes implicated in susceptibility to colorectal cancer. Supplementary Table S5 Selected germline variants. Supplementary Table S6 Estimated cellularity, ploidy and SCNAs in IBD-CRC samples.
Figures S1-S7 from Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease–Associated Colorectal Cancers
Authors: Din Shahida , Wong Kim , Mueller Mike F. , Oniscu Anca , Hewinson James , Black Catherine J. , Miller Martin L. , Jiménez-Sánchez Alejandro , Rabbie Roy , Rashid Mamunar , Satsangi Jack , Adams David J. , Arends Mark J.
Published: April 2023

Supplementary Figure S1: Exome sequencing fold coverage of inflammatory bowel disease associated colorectal cancer cases and matched normal lymph nodes. Supplementary Figure S2 Mismatch repair protein expression analysis. Supplementary Figure S3: CpG island methylation of MLH1 promoter region. Supplementary Figure S4: Rainfall plot for case 21M. Supplementary Figure S5: Proportion of IBC-CRC genomes with SCNAs. Supplementary Figure S6: Nanostring nCounter® pan-cancer immune panel analysis. Supplementary Figure S7: Validation of InDel mutations.
Supplemental Figure 2 from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
Authors: Aggarwal Charu , Thompson Jeffrey C. , Chien Austin L. , Quinn Katie J. , Hwang Wei-Ting , Black Taylor A. , Yee Stephanie S. , Christensen Theresa E. , LaRiviere Michael J. , Silva Benjamin A. , Banks Kimberly C. , Nagy Rebecca J. , Helman Elena , Berman Abigail T. , Ciunci Christine A. , Singh Aditi P. , Wasser Jeffrey S. , Bauml Joshua M. , Langer Corey J. , Cohen Roger B. , Carpenter Erica L.
Published: April 2023

Overall response to pembrolizumab monotherapy (n=31, left) and combination therapy (n=34*, right).
Supplementary figure legends from Radiation with STAT3 Blockade Triggers Dendritic Cell–T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy
Authors: Ott Martina , Kassab Cynthia , Marisetty Anantha , Hashimoto Yuuri , Wei Jun , Zamler Daniel , Leu Jia-Shiun , Tomaszowski Karl-Heinz , Sabbagh Aria , Fang Dexing , Gupta Pravesh , Priebe Waldemar , Zielinski Rafal J. , Burks Jared K. , Long James P. , Kong Ling-Yuan , Fuller Gregory N. , DeGroot John , Sulman Erik P. , Heimberger Amy B.
Published: April 2023

Supplementary Figure legends
Supplemental Figure 1 from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
Authors: Aggarwal Charu , Thompson Jeffrey C. , Chien Austin L. , Quinn Katie J. , Hwang Wei-Ting , Black Taylor A. , Yee Stephanie S. , Christensen Theresa E. , LaRiviere Michael J. , Silva Benjamin A. , Banks Kimberly C. , Nagy Rebecca J. , Helman Elena , Berman Abigail T. , Ciunci Christine A. , Singh Aditi P. , Wasser Jeffrey S. , Bauml Joshua M. , Langer Corey J. , Cohen Roger B. , Carpenter Erica L.
Published: April 2023

Development and validation of a plasma-based panel for mutation detection and assessment of TMB.
Supplementary Data from A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models
Authors: Zheng Long , Ren Luqing , Kouhi Aida , Khawli Leslie A. , Hu Peisheng , Kaslow Harvey R. , Epstein Alan L.
Published: April 2023

Supplementary S1-S8
Table S1 from Lineage-Specific Alterations in Gynecologic Neoplasms with Choriocarcinomatous Differentiation: Implications for Origin and Therapeutics
Authors: Xing Deyin , Zheng Gang , Pallavajjala Aparna , Schoolmeester J. Kenneth , Liu Yuehua , Haley Lisa , Hu Yan , Liu Li , Logan Lisa , Lin Yuan , Pearce Kathryn E. , Sattler Christopher A. , Tsai Ya Chea , Vang Russell , Hung Chien-Fu , Wu T.-C. , Ronnett Brigitte M.
Published: April 2023

Supplementary Table S1
Supplementary Figures and Methods from CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols
Authors: Seo Jai Woong , Tavaré Richard , Mahakian Lisa M. , Silvestrini Matthew T. , Tam Sarah , Ingham Elizabeth S. , Salazar Felix B. , Borowsky Alexander D. , Wu Anna M. , Ferrara Katherine W.
Published: April 2023

Supplementary Figures and Methods
Data S1 from KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Authors: Misale Sandra , Fatherree Jackson P. , Cortez Eliane , Li Chendi , Bilton Samantha , Timonina Daria , Myers David T. , Lee Dana , Gomez-Caraballo Maria , Greenberg Max , Nangia Varuna , Greninger Patricia , Egan Regina K. , McClanaghan Joseph , Stein Giovanna T. , Murchie Ellen , Zarrinkar Patrick P. , Janes Matthew R. , Li Lian-Sheng , Liu Yi , Hata Aaron N. , Benes Cyril H.
Published: April 2023

Supplementary Data 1
Supplementary Data from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Authors: Kelley Robin Kate , Meyer Tim , Rimassa Lorenza , Merle Philippe , Park Joong-Won , Yau Thomas , Chan Stephen L. , Blanc Jean-Frederic , Tam Vincent C. , Tran Albert , Dadduzio Vincenzo , Markby David W. , Kaldate Rajesh , Cheng Ann-Lii , El-Khoueiry Anthony B. , Abou-Alfa Ghassan K.
Published: April 2023

Supplementary Data_Clean File
Tables S1 and S1 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
Authors: Iglesias-Gato Diego , Thysell Elin , Tyanova Stefka , Crnalic Sead , Santos Alberto , Lima Thiago S. , Geiger Tamar , Cox Jürgen , Widmark Anders , Bergh Anders , Mann Matthias , Flores-Morales Amilcar , Wikström Pernilla
Published: April 2023

Tables S1 and S2
Figure S3 from Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy
Authors: Yang Linlin , Shen Changxian , Pettit Cory J. , Li Tianyun , Hu Andrew J. , Miller Eric D. , Zhang Junran , Lin Steven H. , Williams Terence M.
Published: April 2023

Kaplan-Meier survival curves demonstrating percent of mice free from tumor doubling are shown for both FLO1 and OE33 xenograft models.
Supplemental Figure 1 from Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma
Authors: Chi Yihebali , Fang Zhiwei , Hong Xiaonan , Yao Yang , Sun Ping , Wang Guowen , Du Feng , Sun Yongkun , Wu Qiong , Qu Guofan , Wang Shusen , Song Jianmin , Yu Jianchun , Lu Yongkui , Zhu Xia , Niu Xiaohui , He Zhiyong , Wang Jinwan , Yu Hao , Cai Jianqiang
Published: April 2023

Kaplan-Meier curves for progression-free survival (A) and overall survival (B) of the initial 43 patients and the subsequent 123 patients enrolled.
Supplementary Figure from Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Authors: Xie Changqing , Duffy Austin G. , Brar Gagandeep , Fioravanti Suzanne , Mabry-Hrones Donna , Walker Melissa , Bonilla Cecilia Monge , Wood Bradford J. , Citrin Deborah E. , Gil Ramirez Elizabeth M. , Escorcia Freddy E. , Redd Bernadette , Hernandez Jonathan M. , Davis Jeremy L. , Gasmi Billel , Kleiner David , Steinberg Seth M. , Jones Jennifer C. , Greten Tim F.
Published: April 2023

Supplemental figure S1: Representative immunochemistry staining of MHC-1 from tumor biopsied samples of partial response (top), stable disease (middle), and progressive disease (bottom), respectively. Scale bar: 20 X.
Figure S2 from Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
Authors: Hargrave Darren R. , Bouffet Eric , Tabori Uri , Broniscer Alberto , Cohen Kenneth J. , Hansford Jordan R. , Geoerger Birgit , Hingorani Pooja , Dunkel Ira J. , Russo Mark W. , Tseng Lillian , Dasgupta Kohinoor , Gasal Eduard , Whitlock James A. , Kieran Mark W.
Published: April 2023

Investigator-assessed percent change at maximum reduction from baseline in tumor measurement per RANO criteria
Supplementary Data from Association of CD4+ Radiation-Induced Lymphocyte Apoptosis with Fibrosis and Telangiectasia after Radiotherapy in 272 Breast Cancer Patients with >10-Year Follow-up
Authors: Veldwijk Marlon R. , Seibold Petra , Botma Akke , Helmbold Irmgard , Sperk Elena , Giordano Frank A. , Gürth Nicole , Kirchner Anne , Behrens Sabine , Wenz Frederik , Chang-Claude Jenny , Herskind Carsten
Published: April 2023

Supplementary Tables and Figures
Supplementary Figure S4 from Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer
Authors: Lee Jie , Chang Chih-Long , Lin Jhen-Bin , Wu Meng-Hao , Sun Fang-Ju , Jan Ya-Ting , Hsu Shih-Ming , Chen Yu-Jen
Published: April 2023

Kaplan-Meier curve demonstrating overall survival according to pre-treatment sarcopenia groups using cut-off value for skeletal muscle index published by Prado et al.
Supplemental Data from A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors
Authors: Atrafi Florence , Groen Harry J.M. , Byers Lauren A. , Garralda Elena , Lolkema Martijn P. , Sangha Randeep S. , Viteri Santiago , Chae Young Kwang , Camidge D. Ross , Gabrail Nashat Y. , Hu Beibei , Tian Tian , Nuthalapati Silpa , Hoening Elizabeth , He Lei , Komarnitsky Philip , Calles Antonio
Published: April 2023

Table S1. Tolerability of veliparib, carboplatin, and etoposide over entire combination cycles treatment period Table S2. Mean {plus minus} SD (% CV) pharmacokinetic parameters of veliparib following oral administration of veliparib in combination with carboplatin and etoposide on Cycle 1 Day 1 Figure S1. Mean (+SD) dose normalized etoposide plasma concentration-time profile with and without veliparib co-administration Table S3. Pharmacokinetic parameters of etoposide {plus minus} veliparib Table S4. Objective response rate in biomarker cohort by tumor type and veliparib dose level Figure S2. Tumor response and time on study for all dosed patients (n=39) Figure S3. Progression-free survival by disease type Figure S4. Confirmed objective response by gene type in small cell lung cancer samples (n=17)
Supplementary Table 4 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Authors: Rubio Carolina , Martínez-Fernández Mónica , Segovia Cristina , Lodewijk Iris , Suarez-Cabrera Cristian , Segrelles Carmen , López-Calderón Fernando , Munera-Maravilla Ester , Santos Mirentxu , Bernardini Alejandra , García-Escudero Ramón , Lorz Corina , Gómez-Rodriguez Maria José , de Velasco Guillermo , Otero Irene , Villacampa Felipe , Guerrero-Ramos Felix , Ruiz Sergio , de la Rosa Federico , Domínguez-Rodríguez Sara , Real Francisco X. , Malats Núria , Castellano Daniel , Dueñas Marta , Paramio Jesus M.
Published: April 2023

Supplementary Table 4: Spreadsheet of transcriptomic data
Supplemental Figure 1 from Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid
Authors: Liu Yang , Pang Ying , Zhu Boqun , Uher Ondrej , Caisova Veronika , Huynh Thanh-Truc , Taieb David , Hadrava Vanova Katerina , Ghayee Hans Kumar , Neuzil Jiri , Levine Mark , Yang Chunzhang , Pacak Karel
Published: April 2023

Supplemental Figure 1
Table S3 from Periostin and Epithelial–Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma
Authors: Piano Maria Assunta , Brunello Antonella , Cappellesso Rocco , Del Bianco Paola , Mattiolo Adriana , Fritegotto Chiara , Montini Barbara , Zamuner Carolina , Del Fiore Paolo , Rastrelli Marco , Sommariva Antonio , De Salvo Gian Luca , Montesco Maria Cristina , Rossi Carlo Riccardo , Zagonel Vittorina , Calabrò Maria Luisa
Published: April 2023

Periostin detection by IHC.
Supplementary Data Figure 1 from Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer
Authors: Matuszewska Kathy , Santry Lisa A. , van Vloten Jacob P. , AuYeung Amanda W.K. , Major Pierre P. , Lawler Jack , Wootton Sarah K. , Bridle Byram W. , Petrik Jim
Published: April 2023

Supplementary Figure 1 Supplementary Data, Figure 1. Combination therapy results in decreased ascites fluid volume. At euthanasia, ascites fluid was aspirated from the abdomen of control and treated mice and the volume was quantified. Combined treatment with 3TSR and NDV(F3aa) resulted in a significant reduction in ascites volume compared to controls or other treatment groups. Means+/- SEM are shown. Data represents results from N=12 animals per experimental group. Data were analyzed by one-way analysis of variance with Tukey's multiple comparison test; *P<0.05.
Supplementary Figures 1-9 from Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma
Authors: Ishida Chiaki T. , Zhang Yiru , Bianchetti Elena , Shu Chang , Nguyen Trang T.T. , Kleiner Giulio , Sanchez-Quintero Maria J. , Quinzii Catarina M. , Westhoff Mike-Andrew , Karpel-Massler Georg , Prabhu Varun V. , Allen Joshua E. , Siegelin Markus D.
Published: April 2023

Supplementary Figures
Figure S4 from ΔNp63γ/SRC/Slug Signaling Axis Promotes Epithelial-to-Mesenchymal Transition in Squamous Cancers
Authors: Srivastava Kirtiman , Pickard Adam , Craig Stephanie G. , Quinn Gerard P. , Lambe Shauna M. , James Jacqueline A. , McDade Simon S. , McCance Dennis J.
Published: April 2023

Figure S4 shows (A) protein expressions of Src-pY416, total Src and β-actin in Scram siRNA (control), Slug siRNA mol-1 and mol-2 transfected E6/E7-HFK; (B) Phase contrast images indicating EMT (red arrows) and normal (green asterisk) morphology in Scram and Src mol-1 siRNA transfected E6/E7-HFK. (C-D) Protein expressions of total Src, Src-pY416, Slug, vimentin, E-cadherin and β-actin in lysates from non-invasive HFK expressing either GFP or constitutively active Src (Src-531). Phase contrast images indicating EMT (red arrows) and normal (green asterisk) morphology in these cells. Scale bars represented as 100μm. N=3 independent experiments.
Supplementary Data from A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer
Authors: Henry Kelly E. , Dacek Megan M. , Dilling Thomas R. , Caen Jonathan D. , Fox Ian L. , Evans Michael J. , Lewis Jason S.
Published: April 2023

Supplementary Data file with additional experimental and figures. SUPPLEMENTAL FIGURE 1: Radiolabeling of [89Zr]Zr-transferrin as shown by instant thin layer chromatography. Radiochemical yield ranged from 60-70% and all radiochemical purity was >99%. SUPPLEMENTAL FIGURE 2: Protein analysis of drug treatment with BRD4 and ERK inhibitors in human PDAC cells via western blot. SUPPLEMENTAL FIGURE 3: Ex vivo immunohistochemistry of resected murine iKras*p53* tumors. SUPPLEMENTAL FIGURE 4: Dosing regimen for BRD4 and ERK inhibitors (indicated as "drug" in the scheme) over the course of 7 days, with a total of 12 doses, 12 hours apart. The timeline of [89Zr]Zr-transferrin radiotracer administration is indicated on day 5, with PET imaging and biodistribution on day 7, 48 h post-injection with the radiotracer. SUPPLEMENTAL FIGURE 5: Ex vivo immunohistochemistry of resected human PDAC tumors pre and post-treatment with JQ1. Differences in MYC and TfR protein expression can be observed in tumors that responded to JQ1 treatment with regards to [89Zr]Zr-transferrin uptake in vivo. SUPPLEMENTAL FIGURE 6: PET imaging of [89Zr]Zr-Transferrin uptake in vehicle vs. SCH772984-treated animals bearing BxPC-3 (KRAS-WT) xenografts.
Supplementary Figure S1 from FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome
Authors: Kasamon Yvette L. , Chen Haiyan , de Claro R. Angelo , Nie Lei , Ye Jingjing , Blumenthal Gideon M. , Farrell Ann T. , Pazdur Richard
Published: April 2023

Response to mogamulizumab-kpkc according to CCR4 expression level per skin biopsy immunohistochemistry
Table S9 from The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas
Authors: Huang Manling , He Minghui , Guo Yu , Li Heping , Shen Shunli , Xie Yubin , Li Xiaoxing , Xiao Han , Fang Lujing , Li Dongming , Peng Baogang , Liang Lijian , Yu Jun , Kuang Ming , Xu Lixia , Peng Sui
Published: April 2023

Table S9 shows potentially functional mutations of immune-related genes in the six HCC patients with WGS analysis.
Table S3 from The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas
Authors: Huang Manling , He Minghui , Guo Yu , Li Heping , Shen Shunli , Xie Yubin , Li Xiaoxing , Xiao Han , Fang Lujing , Li Dongming , Peng Baogang , Liang Lijian , Yu Jun , Kuang Ming , Xu Lixia , Peng Sui
Published: April 2023

Table S3 shows summary of whole genome sequencing in the six patients with two tumor nodules in the liver.
Figures S1-S6 from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Authors: Howard Thomas P. , Oberlick Elaine M. , Rees Matthew G. , Arnoff Taylor E. , Pham Minh-Tam , Brenan Lisa , DoCarmo Mariana , Hong Andrew L. , Kugener Guillaume , Chou Hsien-Chao , Drosos Yiannis , Mathias Kaeli M. , Ramos Pilar , Seashore-Ludlow Brinton , Giacomelli Andrew O. , Wang Xiaofeng , Freeman Burgess B. , Blankenship Kaley , Hoffmann Lauren , Tiv Hong L. , Gokhale Prafulla C. , Johannessen Cory M. , Stewart Elizabeth A. , Schreiber Stuart L. , Hahn William C. , Roberts Charles W.M.
Published: April 2023

Combined supplementary figures with accompanying legends.
Figure S6 from Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)
Authors: Da Silva Diane M. , Enserro Danielle M. , Mayadev Jyoti S. , Skeate Joseph G. , Matsuo Koji , Pham Huyen Q. , Lankes Heather A. , Moxley Katherine M. , Ghamande Sharad A. , Lin Yvonne G. , Schilder Russell J. , Birrer Michael J. , Kast W. Martin
Published: April 2023

Figure S6 shows the association of circulating cytokine levels with objective clinical response.
Table S6 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Table.S6: Gene sets enriched in B16F10 tumors treated with anti-PD-L1 + swainsonine vs swainsonine + IgG. Pre-ranked gene set enrichment analysis (GSEA) was used to perform the analysis
Figure S5 from Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)
Authors: Da Silva Diane M. , Enserro Danielle M. , Mayadev Jyoti S. , Skeate Joseph G. , Matsuo Koji , Pham Huyen Q. , Lankes Heather A. , Moxley Katherine M. , Ghamande Sharad A. , Lin Yvonne G. , Schilder Russell J. , Birrer Michael J. , Kast W. Martin
Published: April 2023

Figure S5 shows circulating cytokine analysis of each patient from baseline, post-CRT and post-ipilimumab time points.
Table S5 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Table.S5: Gene sets enriched in control tumors treated with anti-PD-L1 vs IgG isotype control. Pre-ranked gene set enrichment analysis (GSEA) was used to perform the analysis.
Figure S3 from Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)
Authors: Da Silva Diane M. , Enserro Danielle M. , Mayadev Jyoti S. , Skeate Joseph G. , Matsuo Koji , Pham Huyen Q. , Lankes Heather A. , Moxley Katherine M. , Ghamande Sharad A. , Lin Yvonne G. , Schilder Russell J. , Birrer Michael J. , Kast W. Martin
Published: April 2023

Figure S3 shows the association of changes in circulating T cell memory subsets with clinical response.
Table S3 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Table.S3: Gene sets enriched in Man2a1-null B16F10 tumors vs control tumors treated with anti-PD-L1. Pre-ranked gene set enrichment analysis (GSEA) was used to perform the analysis.
Figure S2 from Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)
Authors: Da Silva Diane M. , Enserro Danielle M. , Mayadev Jyoti S. , Skeate Joseph G. , Matsuo Koji , Pham Huyen Q. , Lankes Heather A. , Moxley Katherine M. , Ghamande Sharad A. , Lin Yvonne G. , Schilder Russell J. , Birrer Michael J. , Kast W. Martin
Published: April 2023

Figure S2 shows the association of T cell subsets and T cell activation status to ipilimumab dose level received.